Treatment Of Postmenopausal Symptoms Research Articles

P296 Efficacy and tolerability of the 7-day transdermal estradiol patch S21102 in the treatment of postmenopausal symptoms

P296 Efficacy and tolerability of the 7-day transdermal estradiol patch S21102 in the treatment of postmenopausal symptoms

93218151 A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms

93218151 A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms

Effects and acceptability of a new 17β-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints

The treatment of postmenopausal symptoms was studied in 26 healthy women using a new synthetic rubber (Kraton D 2109) vaginal ring containing 53 mg of 17β-oestradiol. All women were postmenopausal, at least 6 months after the last vaginal bleeding and suffering from daily hot flushes. The study was conducted in a double-blind placebo-controlled intrapatient cross-over fashion, and the study period was 6 months. The rings used give an initial in vitro release rate of 0.4 mg/E 2 per day. The in vitro release rate decreases to about 0.2 mg/day after 20 days and levels off asymptotically to about 0.1 mg/day after 50 days. Serum E 2 levels equivalent to the follicular phase of the normal menstrual cycle were measured after 1 month's use, and serum E 2 level stayed above postmenopausal levels throughout the study period. FSH was suppressed during use of the E 2-releasing vaginal ring, while LH showed no statistically significant suppression in continued use. Postmenopausal complaints were recorded by Visual Analogue Scales (VAS) as judged by both the patient and the examining doctor; all complaints had favourable outcomes during use of the E 2-releasing vaginal ring without deterioration of symptoms during use of the placebo ring. No serious side-effects were encountered, and the possibility of managing all postmenopausal complaints with intravaginal oestrogen treatment is discussed.

Oral Medroxyprogesterone in the Treatment of Postmenopausal Symptoms

A double-blind crossover study was designed to compare the effects of placebo and medroxyprogesterone acetate, 20 mg, on vasomotor flushes and blood hormones in 27 postmenopausal women. In women receiving placebo, vasomotor flushes were decreased by 25.9% during the last four weeks of treatment compared with baseline, and a further decrease of 34.5% was achieved by the last four weeks after patients were given medroxyprogesterone. In women who initially took medroxyprogesterone, there a 73.9% decline by the last four weeks in the number of vasomotor flushes. However, when these women were given placebo, an immediate worsening of their symptoms occurred. The drug produced a decline of 27% and 29% in serum levels of follicle-stimulating hormone and luteinizing hormone, respectively, while the serum prolactin level rose slightly. Thus, medroxyprogesterone can be used to treat the vasomotor flushes of postmenopausal women when estrogen use is undesirable.

Oral medroxyprogesterone in the treatment of postmenopausal symptoms

Oral medroxyprogesterone in the treatment of postmenopausal symptoms